Stock analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. The firm’s 50-day simple moving average is $0.14.
About Nabriva Therapeutics
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- MarketBeat Week in Review – 4/29 – 5/3
- How to Find Undervalued Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Which Wall Street Analysts are the Most Accurate?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.